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to 11%-16% of ezetimibe users, and 11%-19% of fibrate users. Nearly 4% of sta-
tin users augmented their regimen during the year, compared with 56%-61% of 
ezetimibe and 38%-51% of fibrate users. The proportion of patients not meeting the 
LDL-C target was 71% and 69% in the CV High Risk and CV Event History cohorts at 
index, respectively, and 65% for both at 12 months. Approximately 60% of diabetic 
patients of CV High Risk cohort did not meet LDL-C target at both index and 12 
months. ConClusions: Adherence to LMT after CV events was best for statins. 
Patients receiving fibrates or ezetimibe had higher rates of switching or augmenta-
tion. LDL-C goal attainment is low, representing a substantial unmet medical need.
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BACkground: Use of antipsychotic medications has been associated with 
increased risk of mortality; however, this association remains questionable given 
conflicting evidence in the literature. oBjeCtives: We conducted a systematic 
review and meta-analysis of observational studies to determine whether mortal-
ity was higher among antipsychotic (AP) users than AP nonusers. Methods: All 
articles published from 1970 to March 2015 were identified by comprehensively 
searching PubMed, MEDLINE, and EMBASE without language restrictions. Three 
reviewers independently extracted study characteristics and indicators of study 
quality. Random or fixed effects models were used to calculate pooled odd ratios 
(ORs) and evaluate heterogeneity (I2). results: We identified 17 (13 cohort and 4 
case-control) eligible studies with 123,116 deaths. Use of APs was associated with 
increased risk of all-cause mortality [OR 1.38, 95% confidence interval (CI) 1.12-1.69, 
I2 = 91.0%] and significantly higher risk of sudden cardiac death [OR 2.24, 95% CI 
1.71-2.92, I2 = 22.8%]. Compared to AP nonusers, the pooled OR for risk of death 
was 1.49 [95% CI 1.20-1.85, I2 = 84.3%] with first-generation antipsychotics (FGAs) 
exposure and 1.50 [95% CI 1.24-1.81, I2 = 89.3%] with second-generation antipsychot-
ics (SGAs) exposure. Subgroup analysis reported that current users of FGAs were at 
a higher risk of mortality [OR 1.78, 95% CI 1.67-1.90, I2 = 0%]. The pooled OR from 
current use of SGAs was 1.81 [95% CI 1.44-2.28, I2 = 85.3%]. Use of FGAs and SGAs 
among elderly patients was associated with a lower risk of death with a pooled OR 
of 1.13 [95% CI 0.69-1.85, I2 = 87.1%] and 1.36 [95% CI 0.90-2.05, I2 = 91.7%], respec-
tively. ConClusions: APs use, especially current users of SGAs, was associated 
with an increased risk of all-cause mortality. Exposure to APs was associated with 
a greater increase in sudden cardiac death. We did not observe a significant differ-
ence between subgroup analyses of FGAs and SGAs.
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oBjeCtives: There are several factors that affect the risk of developing dementia. 
Various studies have shown that defined diagnoses and medications increase or 
decrease dementia risk. But the relatively small numbers of dementia patients 
in some of these studies make the interpretation of their results difficult. The 
aim of this work was to estimate risk factors for dementia in German primary 
care patients. Methods: The case-control study included 11,956 primary care 
patients in the age group 70-90 years with first dementia diagnosis during the 
index period (01/2010-12/2014) (Disease Analyser, Germany). Furthermore, 11,956 
controls without any dementia diagnosis were included after individual match-
ing (1:1) to dementia cases on age, sex, type of health insurance and physician. 
The practice visit records were used to determine 10-year prior index continuous 
follow-up. Multivariate logistic regression models were fitted with dementia as 
dependent variable and the potential predictors. results: Mean age of patients 
and controls was 80.4 (SD: 5.3) years. 39.0% of them were male and 1.9% had a 
private health insurance. In multivariate regression model, the following variables 
were significantly related to an increased risk for dementia: diabetes (OR: 1.17; 
95% CI: 1.10-1.24), lipid metabolism (OR: 1.07; 1.00-1.14), stroke incl. TIA (OR: 1.68; 
1.57-1.80), Parkinson disease (OR: 1.89; 1.64-2.19), intracranial injury (OR: 1.30; 1.00-
1.70), coronary heart disease (OR: 1.06; 1.00-1.13), mild cognitive impairment (OR: 
2.12; 1.82-2.48), mental and behavioural disorders due to use of alcohol (OR: 1.96; 
1.50-2.57). Use of statin (OR: 0.94; 0.90-0.99) and proton-pump inhibitors (PPI) (OR: 
0.93; 0.90-0.97) were protective for the incidence of dementia. ConClusions: Risk 
factors for dementia found in this study were in line with the literature. There is 
also evidence for a protective effect of statin use with respect to the incidence 
dementia. Further studies are required to investigate the association between PPIs 
and a decreased risk of dementia.
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oBjeCtives: The objective of EUnetHTA is to strengthen the practical application of 
tools and approaches to cross-border HTA collaboration. Rapid relative effectiveness 
assessments (REAs) are jointly produced, aiming for efficiency gains and applica-
tion in a national context. The 5th REA concerned the assessment of Vorapaxar, 
indicated in the reduction of thrombotic cardiovascular events in patients with 
a history of myocardial infarction. Methods: Assessment was done using the 
HTA Core Model for Rapid REA, developed by EUnetHTA. The project duration was 
10months and consisted of a scoping phase of 4months, followed by an assess-
ment phase of 6months after the positive CHMP opinion. The project was coordi-
nated by The Dutch Healthcare Institute. The main author of the report was French 
national authority for health, with the Ministry of Health of Slovakia as co-author. 
Six other European agencies were involved as reviewers in the different assessment 
steps. The marketing authorization holder (MAH) was provided the opportunity to 
review the report. results: Assessment report included 4 domains: health prob-
lem, description of the technology, clinical effectiveness and safety, and has been 
published on 19/06/2015. Vorapaxar is a selective antagonist of PAR-1 (thrombin 
receptor platelets). The MAH provided TRA 2°P-TIMI 50 trial to evaluate safety and 
efficacy of vorapaxar as an add-on therapy : vorapaxar + ASA ± clopidogrel versus 
ASA ± clopidogrel in subjects with a history of myocardial infarction. The results 
and experiences of the joint assessment will be provided during the ISPOR congress. 
Also we will discuss the extent to which national adaptation of the report takes 
place. ConClusions: HTA agencies have shown that they are able to provide a 
common assessment, using common guidelines, even within the different pro-
cesses and reimbursement systems they are using. The joint assessment process 
is evaluated regularly by the agencies involved. This improves the core model and 
the procedures.
PCv182
rEvEALED OPPOrTUNiSM: HOw PHySiCiANS gAME PriOr AUTHOrizATiON 
PrOTOCOLS UNTiL THEy ArE rESCiNDED
Kahan NR1, Chinitz D2, Waitman D1
1Leumit Health Services, Tel-Aviv, Israel, 2Hebrew University, Jerusalem, Israel
oBjeCtives: Prior authorization (PA) is a managerial technique frequently imple-
mented to curtail use of expensive drugs and to improve drug-prescribing quality. 
PA requirements may incentivize physicians to document adverse effects (AEs) to 
drugs, sometimes falsely, to meet eligibility-requirements for approval. The objec-
tive of this study was to evaluate the effect of a PA requirement on documentation 
rates of AEs of drugs necessary for approval of more expensive drugs. Methods: 
We conducted a retrospective analysis of physician electronic-reporting behav-
ior of AEs to angiotensin converting enzyme inhibitors (ACE-Is) before and after 
revocation of a PA requirement for angiotensin receptor blockers (ARBs) during 
the years 2004-2013 in an Israeli HMO. Data were stratified by newly treated and 
patients who had been treated for at least one year. The annual rate of AEs to 
ACE-Is in treated patients (number of reported cases of AEs per 1000 ACE-I treated 
patients) was calculated for the five years before and after revocation of the PA 
constraint. results: 151,845 patients met inclusion criteria of the study. AE rates 
amongst newly treated patients peaked to 10.0 cases per 1000 patients during 
2007 gradually falling to 4.6 after the PA requirement was rescinded (P< 0.001). 
Amongst previously treated patients a fall from 5.4/ 1000 to 1.8/1000 patients was 
observed. ConClusions: The PA requirement under investigation was observed 
to be significantly associated with physician propensity for reporting drug side-
effects, possibly erroneously. The decline in incidence of reported of side-effects 
in both subpopulations upon revocation of the PA requirement confirm our sus-
picion that physicians were incentivized to document side effects to ACE-Is to 
meet eligibility-requirements for approval of ARBs. The risk of gaming behavior 
in documentation of drug side effects may increase when side effects cannot be 
substantiated with laboratory tests or diagnostic imaging.
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oBjeCtives: To estimate real-world utilisation of lipid modifying therapy (LMT) 
and low-density lipoprotein cholesterol (LDL-C) goal attainment in the United 
Kingdom. Methods: Individuals with their first and, if present, repeated car-
diovascular (CV) related hospitalisations were identified from 2006-2012 Clinical 
Practice Research Datalink and Hospital Episode Statistics data. Patients > 18 years 
receiving LMT within 180 days before the CV (index) event were followed for 12 
months. Patient cohorts were classified as CV Low/Moderate Risk, CV High Risk, and 
CV Event History. Adherence (medication possession ratio), persistence, switching, 
and therapy augmentation were calculated for statins, ezetimibe and fibrates during 
the follow-up period. Attainment of the recommended LDL-C target of < 1.8 mmol/L 
was assessed for risk groups at the index and 12 months afterward. results: 
Across cohorts, 97% were receiving statins before or at index. Moderate intensity 
statins were used the most. Medication possession ratio ranged from 0.76-0.79 for 
statins, 0.72-0.79 for ezetimibe, and 0.58-0.73 for fibrate users. Persistence at 12 
months was 51%-52% for statin, 40%-50% for ezetimibe, and 36%-45% for fibrate 
users. Approximately 2% of statin users switched to new medications, compared 
